Evidence map›Paper›PMID 30579534›Full record

ArticleThe Journal of thoracic and cardiovascular surgery2019

Delivery of progenitor cells with injectable shear-thinning hydrogel maintains geometry and normalizes strain to stabilize cardiac function after ischemia.

Ann C Gaffey, Minna H Chen, Alen Trubelja, Chantel M Venkataraman, Carol W Chen, Jennifer J Chung, Susan Schultz, Chandra M Sehgal, Jason A Burdick, Pavan Atluri

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of thoracic and cardiovascular surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Cell augmentation strategies for cardiac stem cell therapies.Stem cells translational medicine · 2021
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Injectable Hydrogel-Based Nanocomposites for Cardiovascular Diseases.Frontiers in bioengineering and biotechnology · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ann C GaffeyDivision of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, Pa.
Minna H ChenDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pa.
Alen TrubeljaDivision of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, Pa.
Chantel M VenkataramanDivision of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, Pa.
Carol W ChenDivision of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, Pa.
Jennifer J ChungDivision of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, Pa.
Susan SchultzDepartment of Radiology, University of Pennsylvania, Philadelphia, Pa.
Chandra M SehgalDepartment of Radiology, University of Pennsylvania, Philadelphia, Pa.
Jason A BurdickDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pa.
Pavan AtluriDivision of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, Pa. Electronic address: Pavan.atluri@uphs.upenn.edu.
University of Pennsylvania · US

Funding

Overall: Resource-based Center for Musculoskeletal Disorders Research (Overall Application)P30AR069619 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI LOUIS J SOSLOWSKY · 2016 to 2026
$9.1M
Engineered Stem Cell Microenvironments for controlled VasculogenesisR01HL107938 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI GERECHT, SHARON · 2011 to 2015
$2.1M
Localized Targeting of Matrix Proteases Following Myocardial InfarctionR01HL111090 · NHLBI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI BURDICK, JASON A, SPINALE, FRANCIS G · 2012 to 2015
$2.0M
NHLBI NIH HHS R01 HL107938NHLBI NIH HHS R01 HL111090NIAMS NIH HHS P30 AR069619
6 · The paper itself

Abstract

objectivesThe ventricle undergoes adverse remodeling after myocardial infarction, resulting in abnormal biomechanics and decreased function. We hypothesize that tissue-engineered therapy could minimize postischemic remodeling through mechanical stress reduction and retention of tensile myocardial properties due to improved endothelial progenitor cell retention and intrinsic biomechanical properties of the hyaluronic acid shear-thinning gel.

methodsEndothelial progenitor cells were harvested from adult Wistar rats and resuspended in shear-thinning gel. The constructs were injected at the border zone of ischemic rat myocardium in an acute model of myocardial infarction. Myocardial remodeling, tensile properties, and hemodynamic function were analyzed: control (phosphate-buffered saline), endothelial progenitor cells, shear-thinning gel, and shear-thinning gel + endothelial progenitor cells. Novel high-resolution, high-sensitivity ultrasound with speckle tracking allowed for global strain analysis. Uniaxial testing assessed tensile biomechanical properties.

resultsShear-thinning gel + endothelial progenitor cell injection significantly increased engraftment and retention of the endothelial progenitor cells within the myocardium compared with endothelial progenitor cells alone. With the use of strain echocardiography, a significant improvement in left ventricular ejection fraction was noted in the shear-thinning gel + endothelial progenitor cell cohort compared with control (69.5% ± 10.8% vs 40.1% ± 4.6%, P = .04). A significant normalization of myocardial longitudinal displacement with subsequent stabilization of myocardial velocity with shear-thinning gel + endothelial progenitor cell therapy compared with control was also evident (0.84 + 0.3 cm/s vs 0.11 ± 0.01 cm/s, P = .03). A significantly positive and higher myocardial strain was observed in shear-thinning gel + endothelial progenitor cell (4.5% ± 0.45%) compared with shear-thinning gel (3.7% ± 0.24%), endothelial progenitor cell (3.5% ± 0.97%), and control (8.6% ± 0.3%, P = .05). A resultant reduction in dynamic stiffness was noted in the shear-thinning gel + endothelial progenitor cell cohort.

conclusionsThis novel injectable shear-thinning hyaluronic acid hydrogel demonstrates stabilization of border zone myocardium with reduction in adverse myocardial remodeling and preservation of myocardial biomechanics. The cellular construct provides a normalization of strain measurements and reduces left ventricular dilatation, thus resulting in improvement of left ventricular function.

Indexed as

HemodynamicsVentricular Function, LeftVentricular RemodelingAnimalsBiomechanical PhenomenaCells, CulturedCell SurvivalDisease Models, AnimalEndothelial Progenitor CellsGraft SurvivalHyaluronic AcidHydrogelsInjectionsMaleMyocardial InfarctionMyocardiumHyaluronic AcidHydrogelscellular therapyhydrogelischemic myocardiumshear-thinning gel

Identifiers

PMID30579534
PMCPMC7769598
OpenAlexW2901056606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.